These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32855532)

  • 41. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth
    Anastasiadou E; Seto AG; Beatty X; Hermreck M; Gilles ME; Stroopinsky D; Pinter-Brown LC; Pestano L; Marchese C; Avigan D; Trivedi P; Escolar DM; Jackson AL; Slack FJ
    Clin Cancer Res; 2021 Feb; 27(4):1139-1149. PubMed ID: 33208342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
    Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 46. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
    Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
    Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
    Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
    Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repurposing dasatinib for diffuse large B cell lymphoma.
    Scuoppo C; Wang J; Persaud M; Mittan SK; Basso K; Pasqualucci L; Rabadan R; Inghirami G; Grandori C; Bosch F; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16981-16986. PubMed ID: 31383760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
    Liu H; Wei J; Sang N; Zhong X; Zhou X; Yang X; Zhang J; Zuo Z; Zhou Y; Yang S; Du J; Zhao Y
    Med Oncol; 2021 Sep; 38(10):124. PubMed ID: 34491469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ferroptosis Markers Predict the Survival, Immune Infiltration, and Ibrutinib Resistance of Diffuse Large B cell Lymphoma.
    Weng J; Chen L; Liu H; Yang XP; Huang L
    Inflammation; 2022 Jun; 45(3):1146-1161. PubMed ID: 35064379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
    Guan J; Huang D; Yakimchuk K; Okret S
    Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
    Wilson WH; Wright GW; Huang DW; Hodkinson B; Balasubramanian S; Fan Y; Vermeulen J; Shreeve M; Staudt LM
    Cancer Cell; 2021 Dec; 39(12):1643-1653.e3. PubMed ID: 34739844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
    Wu X; Ban C; Deng W; Bao X; Tang N; Wu Y; Deng Z; Xiong J; Zhao Q
    Mol Cancer; 2024 Jul; 23(1):144. PubMed ID: 39004737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
    Chen TL; Harrington B; Truxall J; Wasmuth R; Prouty A; Sloan S; Lehman AM; Sampath D; Orlemans E; Baiocchi RA; Alinari L; Byrd JC; Woyach JA; Hertlein E
    J Hematol Oncol; 2021 Feb; 14(1):36. PubMed ID: 33627156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 59. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
    Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
    Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
    Fiskus W; Mill CP; Perera D; Birdwell C; Deng Q; Yang H; Lara BH; Jain N; Burger J; Ferrajoli A; Davis JA; Saenz DT; Jin W; Coarfa C; Crews CM; Green MR; Khoury JD; Bhalla KN
    Leukemia; 2021 Sep; 35(9):2621-2634. PubMed ID: 33654205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.